

## DAFTAR PUSTAKA

- American Cancer Society (ACS), 2018, *Vulvar Cancer*. American Cancer Society, <https://www.cancer.org/cancer/types/vulvar-cancer.html> (diakses pada 9 September 2023).
- Andayani, T.M., 2013, *Farmakoekonomi Prinsip dan Metodologi*, Cetakan I, Bursa Ilmu, Yogyakarta.
- Anny, V.P., 2007, *Perspektif Internasional Penelitian Farmakoekonomi dan Outcome*, Simposium Farmakoekonomi Badan Litbang Kesehatan, Jakarta.
- Aziz, F., Andrijono., Saefudin, A.B., editor., 2006, *Onkologi Ginekologi*, Ed Ke-1, Yayasan Bina Pustaka Sarwono Prawirohardjo, Jakarta.
- Balekdjian, D. dan Russo, M., 2002, *Outcome Based Access: Raising the Bar. Pharmaceutical Executive*, [www.PharmExec.com](http://www.PharmExec.com) (diakses pada 11 September 2023).
- Barlow, P., Konopnicki, D., Manigart, Y., Gilles, C., Marchin JD, Feoli F., 2016, High-risk human papillomavirus genotypes distribution in a cohort of HIVpositive women living in Europe: Epidemiological implication for vaccination against human papillomavirus, *AIDS*. 30(3): 425-433.
- Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA dkk., 2005, Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. *Curr Med Res Opin*, 21:195-206.
- Bootman, J.L., 2005, *Principles of Pharmacoeconomics*, W Harvey Whitney Books Company.
- Budiharto, Martuti, Soewarta, K., 2008, Peranan Farmakoekonomi dalam Sistem Pelayanan Kesehatan Indonesia. *Buletin Penelitian Kesehatan* Vol 11: 337- 340.
- Byford, S., dkk., 2000, Economic Notes: Cost of Illness. *British Medical Journal*. 320(7245): 1335.
- Costa, W.A., Monteiro, M.N., Queiroz, J.F., Gonçalves, A.K., 2017, Pain and quality of life in breast cancer patients. *Clinics (Sao Paulo)*. 72(12):758–63. Available from: <https://pubmed.ncbi.nlm.nih.gov/29319722>.
- Martel, C.D., Plummer, M., Vignat, J., Franceschi, S., 2017, Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int J Cancer*, 141:664-70.
- Departemen Kesehatan RI, 2013, *Pedoman Penerapan Kajian Farmakoekonomi*, 17-26, Kementerian Kesehatan RI, Jakarta.
- Hami, L.T., Lampe, B., Mallmann, P., Foreigner, D., 2018, The Impact of Age on The Prognosis of Vulvar Cancer, *Oncol Res Treat*, 41(9):520-524.
- International Monetary Fund, 2023, *World Economic Outlook Database*, [https://www.imf.org/en/Publications/WEO/weo-database/2023/October/weo-report?c=536.&s=NGDP\\_RPCH,NGDPD,PPPGDP,NGDPDPC,PPPPC,&sy=2](https://www.imf.org/en/Publications/WEO/weo-database/2023/October/weo-report?c=536.&s=NGDP_RPCH,NGDPD,PPPGDP,NGDPDPC,PPPPC,&sy=2)

[022&ey=2028&ssm=0&scsm=1&scc=0&ssd=1&ssc=0&sic=0&sort=country&ds=.&br=1](#), diakses pada 10 Desember 2023.

- Iswari, A., Endarti, D., Trijayanti, C., Haris, R.N.H., Imansari, A.N.R., 2020, Analisis Biaya Penyakit Tuberkulosis: Studi Kasus di Salah Satu Puskesmas dan Rumah Sakit di Yogyakarta, *Majalah Farmaseutik*, Vol. 16 No. 2: 211-217.
- Jacobs, J. C., Barnett, P. G., 2017, Emergent Challenges in Determining Costs for Economic Evaluations. *PharmacoEconomics. Springer International Publishing*, 35(2), pp. 129–139.
- Jefferson, T., Demicheli, V., Mugford, M., Cost-of-illness studies, elementary economic evaluation in health care. 2nd Ed., *London: BMJ Publishing Group*, 2000:17-29.
- Koh, W.J., Greer, B.E., Abu-Rustum, N.R., Apte, S.M., Campos SM, Cho KR, dkk., 2016, *Vulvar Cancer*, National Comprehensive Cancer Network, [www.nccn.org](http://www.nccn.org) (diakses pada 8 September 2023).
- Louchini, R., Ms., Goggin, P, MD, Ms., & Steben, M, D., 2008, The Evolution of HPV-related Anogenital Cancers Reported in Quebec Incidence Rates and Survival Probabilities. *Institut National de Santé Publique Du Québec*, 88(3):99-106.
- Mahumud, R.A., Sarker, A.R., Sultana, M., Islam, Z., Khan, J., dan Morton, A., 2017. Distribution and determinants of out-of-pocket healthcare expenditures in Bangladesh. *Journal of Preventive Medicine and Public Health*, 50: 91–99.
- Makhinova, T., Rascati K., 2013, Pharmacoeconomics Education in US Colleges and Schools of Pharmacy. *Am J Pharm Educ*. 77(7):1-5.
- Masiye, F., dan Kaonga, O., 2016, Determinants of healthcare utilisation and out-of-pocket payments in the context of free public primary healthcare in Zambia, *International Journal of Health Policy and Management*, 5: 693–703.
- Melia, E.K.D.A., Putrayasa, I.D.P.Gd., Azis, A., 2013, *Hubungan Antara Frekuensi Kemoterapi Dengan Status Fungsional Pasien Kanker Yang Menjalani Kemoterapi di RSUP Sanglah Denpasar*, Program Studi Ilmu Keperawatan Fakultas Kedokteran Universitas Udayana, Bali.
- Montana, G.S., Kang, S.K., 2007, *Chapter 72 : Carcinoma of the Vulva*. In :Perez CA, Brady LW (ed.). *Perez and Brady's Principles and Practice of Radiation Oncology*, 5th Edition. Lippincott Williams & Wilkins, Philadelphia.
- Motazedian, N., 2020, Genital Warts Among Men Attending a Dermatology Clinic : Risk Factors and Knowledge, *Int J High Risk Behav Addict*, 9(3):9–11.
- Nurhidayat, W., Ramli I., 2017, Laporan Kasus Kanker Vulva, *Radioterapi & Onkologi Indonesia*, 8(1).
- Östensson, E., Silfverschiöld, M., Greiff, L., Asciutto, C., Wennerberg, J., Lydrup M-L, dkk., 2018, Correction: The economic burden of human papillomavirus-related precancers and cancers in Sweden, *PLoS ONE*, 13(7).

- Pavel, M.S., Chakrabarty, S., dan Gow, J., 2016, Cost of illness for outpatients attending public and private hospitals in Bangladesh, *International journal for equity in health*, 15: 167.
- Potes, V.A.M., Suparman, E., Laihad, B.J., 2017, Profil Penderita Kanker Ginekologi di RSUP Prof. Dr. R. D. Kandou Manado Periode Juli 2015 sampai Juli 2016, *Jurnal Kedokteran Klinik (JKK)*, Vol 1(3); 27.
- Rasjidi, I., 2006, *Epidemiologi Kanker pada Wanita*, Edisi Ke-1, CV. Segung Seto, Jakarta.
- Rasjidi, I., 2009, *Deteksi Dini Pencegahan Kanker pada Wanita*, CV. Segung Seto, Jakarta.
- Rascati, K.L., dkk., 2009, *Essentials of Pharmacoeconomics*, Lippincott Williams & Wilkies, Philadelphia.
- Rini, S., Hanum, F., 2016, Faktor-Faktor yang Memengaruhi Angka Kejadian Kanker Serviks di RSUD Margono Soekarjo Purwokerto, *Viva Medika*, Vol 9 (1); 56.
- Sanchez, L., 2005, *Pharmacoeconomics: Principles, Methods and Applications in Dipiro, J., Talbert, R., Yee, G., Matzke, G., Wells, B., Posey, L. (Eds), Pharmacotherapy: A Pathophysiologic Approach*. McGraw- Hill, United States of America.
- Setiawan, D., Endarti, D., & Suwantika, A. A., 2017, *Farmakoekonomi modeling*, Purwokerto-Press, Purwokerto.
- Segel, B.A., dan Joel, E., 2006, *Cost of Illness Studies- A Primer*, RTI-UNC Center of Excellence in Health Promotion Economics, North Carolina.
- Shafie, A.A., 2011, *Introduction to Economic Evaluation*, disampaikan pada *Workshop Farmakoekonomi dalam Pelayanan Kesehatan*, Universitas Pancasila, Jakarta.
- Shahnaz, D., Lestari, K., 2018, Kajian Farmakoekonomi yang Mendasari Pemilihan Pengobatan di Indonesia, *Farmaka*, 16:134-145.
- Siegel, R.L., Miller, K.D., Jemal, A., 2018, Cancer statistics, *CA Cancer J Clin*, 68(1):7–30.
- Stephens, S., dkk., 2020, The costs of treating vaginal and vulvar cancer in England (2009-2015), *BMC Public Health*, 20(1), 1-8.
- Sugiyono, 2017, *Metode Penelitian Kuantitatif, Kualitatif, R & D*. CV Alfabeta. Bandung.
- Tarricone, R., 2006, Cost-of-illness: what room in health economics?, *Health Policy*, 77:51-63.
- Teni, F.S., Gebresillassie, B.M., Birru, E.M., Belachew, S.A., Tefera, Y.G., Wubishet, B.L., dkk., 2018. Costs incurred by outpatients at a university hospital in northwestern Ethiopia: a cross-sectional study. *BMC Health Services Research*, 18: 1–10.
- Trisnantoro, L., 2005, *Manajemen Rumah Sakit*. Gadjah Mada University Press, Yogyakarta.
- Utaril, A.B., dan Rochmah, T.N., 2017, Analisis *Burden of Disease* Hipertensi pada Masyarakat di Kabupaten Kediri, *The Indonesian Journal/Public Health*, Vol. 14 No. 2; 138-149.

Vogenberg, F. R., 2001, *Introduction to Apply Pharmacoeconomics*, Mc Graw-Hill Companies, USA.